Novo Nordisk lowered its full-year sales forecast for 2025 to 8-14% growth, down from the earlier 13-21% estimate, citing ongoing challenges from cheaper knockoff versions of its obesity drug Wegovy in the U.S. The company also anticipates reduced operating profits. Shares dropped over 20% following the revision. Concurrently, Novo appointed Maziar Mike Doustdar as the new CEO and consolidated R&D units under a single division led by Martin Holst Lange. Despite being a leader in the GLP-1 obesity and diabetes market, Novo’s market share is eroding amid regulatory and competitive pressures, including failed attempts to compete on price and ended marketing partnerships.